Skip to main content
SpringerLink
Log in

Phase II and phase III failures: 2013–2015

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Reasons for clinical trial failures 2013–2015.
Figure 2: Recent trends in clinical trial failures.

Author information

Authors and Affiliations

  1. Richard K. Harrison is the Chief Scientific Officer at Clarivate Analytics, 1500 Spring Garden Street, Philadelphia, Pennsylvania 19103, USA.,

    Richard K. Harrison

Authors
  1. Richard K. Harrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard K. Harrison.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrison, R. Phase II and phase III failures: 2013–2015. Nat Rev Drug Discov 15, 817–818 (2016). https://doi.org/10.1038/nrd.2016.184

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2016.184

  • Springer Nature Limited

This article is cited by

Search

Navigation